More Business Briefs
- Business briefs: Pfizer, Novartis, Boehringer Ingelheim, Elsevier
- Business Briefs: inVentiv; Mylan; Royalty Pharma; Pfizer; Edelman
- Business briefs: Actavis, Bayer, Oramed, Elan
- Business briefs: Pfizer, BMS, CMS, Sanofi
- Business briefs: Bayer, FDA, Ranbaxy
Cephalon reported that selling, general and administrative expenses jumped 30% in the first quarter to $199 million on DTC for narcolepsy drug Provigil (modafinil) and the launch of cancer drug Treanda (bendamustine hydrochloride).